Overview

Whole Blood Bactericidal Activity (WBA) Against Mycobacterium Tuberculosis of Faropenem Plus Amoxicillin/Clavulanic Acid in Healthy Volunteers

Status:
Completed

Trial end date:
2015-10-01

Target enrollment:

Participant gender:

Summary

The purpose of this study is to evaluate the bactericidal activity against Mycobacterium tuberculosis of faropenem boosted with amoxicillin/clavulanic acid. Pharmacokinetics (PK) and Whole blood Bactericidal Activity (WBA) will be measured in healthy volunteers following single doses of faropenem plus amoxicillin/clavulanic acid.

Phase:

Phase 1

Details

Lead Sponsor:

National University Hospital, Singapore

Treatments:

Amoxicillin
Amoxicillin-Potassium Clavulanate Combination
beta-Lactams
Clavulanic Acid
Clavulanic Acids
Rifampin